Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will participate in the upcoming two-day Q3 Virtual Investor Summit. Vivos CEO Kirk Huntsman along with CFO Brad Amman and Ed Loew, Vivos investor relations … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Q3 Virtual Investor Summit”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has scheduled a conference call and live webcast for Aug. 12, 2021, to begin at 5 p.m. ET. The purpose of the call is to … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Discuss Q2 2021 Financial Results”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center”
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of … Continue reading “NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology”
